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tion to the era of factory-scale analysis. The great acceleration of prog-
ress we've seen in other ﬁelds is now coming to healthcare.
At Google, we have more than 15 years of experience with ﬁnding
the value in information. We have built tools to organize information
and make it accessible and useful to people everywhere. Our global
infrastructure, which powers Search,Maps, YouTube, andmore, is avail-
able to everyone via the Google Cloud Platform. Google Genomics isservices to scientists, clinicians, and patients.Nicholas Negroponte, in his 1995 book Being Digital, popularized the
notion of the worlds of Atoms and Bits. The history of civilization to
date was largely fueled by advances in the world of Atoms, with the
19th-century Industrial Revolution marking a notable acceleration:
The Industrial age, very much an age of atoms, gave us the concept of
mass production, with the economies that come frommanufacturing
with uniform and repetitious methods in any one given space and
time.
We were at the beginning of a similar acceleration in the world of
Bits, with an information revolution marked by Tim Berners-Lee's in-
vention of the web browser in 1990. The free ﬂow of information led
to a new kind of scale:
In the information age, mass media got bigger and smaller at the
same time. In the post-information age, we often have an audience
the size of one. Everything is made to order, and information is
extremely personalized.
The world of Bits is continuing to transform the world of Atoms.
Services like Amazon, AirBnB, and Uber show the potential for organizing
information frommany sources, and using it to deliver tailored real-world
experiences to just the right person at just the right time.
Today we're at the beginning of a third revolution, as the world of
Cells enters the world of Bits. New measurement tools, including high-
throughput genomic sequencing, single-cell analysis (Macosko et al.,
2015), andmobile sensors (Otis and Parviz, 2014) are giving researchers
and clinicians access to orders of magnitude more data than they everpotential for understanding al
ing sense of data also bring
dvances in data science, and
. This is an open access articlel
sunderworking to bring similar tools to theworld of Cells, and provide scalable
In this article, we look at how the combination of data science and
life science, or the worlds of Bits and Cells, could fundamentally change
how patients are treated and how discoveries are made. With so many
researchers working hard on the challenge, we believe that precision
medicine is within our reach.1. The vision
Cheap data production and storage have enabled many ﬁelds to
make the leap from qualitative to quantitative, and from one-size-ﬁts-
all to precision value delivery. Consider weather forecasts: as satellites
and sensors around the world collect massive amounts of information,
computers have analyzed these data troves to make sense of all sorts
of weather phenomena, resulting in more reliable information on
what tomorrow's weather may bring. Similarly, we witnessed a sea
change in our ability to get around as geographic information became
easier to obtain. Big data has made it possible not only to build accurate
maps of virtually any place on the planet, but also to provide precision
navigation that uses real-time trafﬁc information to automatically
route you around congestion or road construction.
Amazon uses information technology to allow every reader to ﬁnd
just the books (and other products) they want. Companies like AirBnB
and Uber are managing information from global networks of service
providers (property owners, drivers) to give global consumers more
ﬂexibility than was possible with last century's technology. These
new precision services are beneﬁting all users of retail, lodging, and
transportation — that is, all of us.
These and other industries have transformed themselves by using
large-scale computational resources and high-powered analytical tools
to unlock the value in data. Doing the same in biology will lead to new
interventions based on new understanding of the genetic mechanisms
of disease progression and resilience; early warning of impending
disease using individual health data gathered via wearable sensors;
access to knowledge in the untapped troves of clinical data; andthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 2. Data science milestones.
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of prevention and therapy.
This transformation will be accelerated as we ﬁnd ways to free data
now trapped in silos, contributing to a globally accessible resource that
will allow scientists to query not just the data they've generated, but
also data generated by global collaborators and in publicly available
databases. Looking at common diseases or traits in studies requiring
hundreds of thousands or millions of people for statistical signiﬁcance
will no longer be an insurmountable challenge.
Realizing this vision will take organization of large amounts of data,
scalable processing and analysis tools, and updated policies to support
the new possibilities (Fig. 1).
2. Driven by data
Remarkable improvements in the cost of DNA sequencing have
removedmany rate-limiting factors in genomics, shifting the bottleneck
from generating data to interpreting and using that data. Just 15 years
ago, the global scientiﬁc community invested signiﬁcant time and
funding to produce a single human genome sequence; today, the
highest-throughput systems can generate sequence data for nearly 50
genomes per day. In 2013, scientists estimated that the world's
sequencing capacity could generate 15,000 terabytes of compressed
genetic data per year, and that capacity was increasing three- to ﬁve-
fold annually (Schatz and Langmead, 2013).
Cheap sequencing has made large-scale studies possible, and more
are launching all the time. The Autism Speaks MSSNG Project aims to
sequence 10,000 samples from families with autism, leading to what
is expected to be the world's largest database of autism-related
sequencing data. In the UK, the 100,000 Genomes Project is working
to sequence 100,000 people, with early goals of shedding light on rare
diseases and common cancers. 23andMe recently announced that it
had genotyped itsmillionth customer (Wojcicki, 2015). Other examples
include the VA's Million Veteran Program and the Precision Medicine
Initiative announced by President Obama in the 2015 State of the
Union address.
3. A transformation in tools
Having a lot of data is a necessary ﬁrst step, but is not sufﬁcient—we
also need a shift in how we process and interact with biological data.
The knowledge we want to mine from sequencing data will depend
on algorithms that can spot patterns across multiple datasets, ﬁnd
the quietest signals in the noisiest data, and teach themselves to
answer questions better as they crunch more and more information.
Fortunately, the world of data science has been building the tools we
need (Fig. 2).
MapReduce, originally built at Google to regenerate the web index
for better accuracy and speed of Search results (Dean and Ghemawat,
2004), was designed to take advantage of many thousands of proces-
sors, each handling one slice of a task. Since then, the MapReduce
programming model has given birth to a family of tools, including
Hadoop, Spark, Flume, Millwheel, and Dataﬂow. In our tests with data
from the 1000 Genomes Project, we showed that MapReduce-likeFig. 1. Building a virtuous cycle.tools work well on genomic data — in one example, sorting samples
by ancestry using principal component analysis.
Dremel, originally built at Google for interactive analysis of trillion-
row tables (Melnik et al., 2010), uses thousands of disk drives, each
holding a slice of data. By using Google BigQuery, a publicly available
Dremel-based service, we are able to parse terabytes of genomic variant
data and provide answers in seconds. This tool can be used to quickly
detect patterns between genetic variants and disease, populations,
epidemiology, and more.
In The Unreasonable Effectiveness of Data (Halevy et al., 2009), we
learn that in domains where enough data is available, machine intelli-
gence can be extremely effective at ﬁnding patterns and insights, with
initial successes in language translation and speech recognition. Work
in the ﬁeld has continued, with new techniques being developed and
applied to a variety of problem areas.
Deep learning, an approach to automatically ﬁnding the high-level
abstractions beneath the surface of low-level data, is one approach
that has promise for biological datasets. In 2012, we reported (Le et al.,
2012) on using deep learning to detect common objects in 10 million
YouTube videos. Although the computer wasn't told what to look for,
analysis across so many images allowed the algorithms to ﬁnd patterns.
For example, our experiment yielded a composite image of a cat
(Fig. 3); having seen this particular pattern of pixels in so many images,
computers were able to determine that there was something important
about a cat (at least to the YouTube community). Feeding massive geno-
mic and phenotypic datasets into these machine-learning algorithms
could result in pattern detection in the areas of disease progression, the
sequence of genetic variant additions that lead to cancer, gene expression,
and more.
The success of IBM's Watson on Jeopardy! in 2011 was based on
years of machine learning geared to the game show's format. Machine
learning was used in 2014 for auto-captioning, essentially translating
from the language of images into English (Vinyals et al., 2014) (Fig. 4).
Earlier this year, Google reported on how our DeepMind technology
taught itself to play Atari video games (and win!) (Mnih et al., 2015).
The system was able to play at least as well as a professional human
game tester across a set of 49 games, without having any knowledge
of the rules of any of the games.
These examples are not just laboratory experiments— the tools that
make them possible are available today, and the results are in daily use
by many millions of users of speech recognition, language translation,
and more. As experts in data science and life science work together,
and as enough data becomes available to analyze, these algorithms
could teach themselves to auto-annotate patient charts, suggest
diagnoses, spot links between genotype and phenotype, and even
Fig. 5. Interoperability: one API, many apps.
Fig. 3. A commonly found object in YouTube videos.
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patient.
4. Policies and paradigms
Realizing the vision of precision medicine requires more than just
data and tools. We'll need fruitful collaborations among academia and
industry, including people steeped in life sciences as well as experts
from other ﬁelds who can offer solutions that aren't traditionally used
in biology or medicine. Enabling these collaborations requires updates
to the ways we work together.
In theworld of technology, it's long been known that vibrant ecosys-
tems arise from interoperable tools, connected by standard program-
ming interfaces, known as APIs. For example, one reason the Web has
grown as fast as it has is that any web browser (e.g. Chrome, Safari)
can work with any website, so that the providers of information and
consumers of information can evolve separately. Bringing similar inter-
operability to the world of life science information can have similar
beneﬁts.
The Global Alliance for Genomics and Health (GA4GH,
genomicsandhealth.org) is a global partnership with the mission of es-
tablishing standards and policies that allow scaling and responsible
sharing of life science data. The GA4GH has developed a web-based
API, implemented by EBI, Google, and many others, that allows users
to import, process, manage, and analyze genomic data at scale. The
API enables free and open exchange of data across institutions to
facilitate collaborative research and analysis; it also lets users build
their own tools and use tools from others (Fig. 5). Any tool that calls
the API can work with any data repository that exposes the API. WeFig. 4. Generating captions by tranhope this API will allow scientists to ask bigger questions, and the inter-
operability will allow all of us to beneﬁt from each other's work.5. Policy progress
Technical policies like those discussed above remove some barriers
to progress. There are other potential pitfalls that could make it more
challenging to achieve these grand goals. Current practices have evolved
for good reason, and take time to change to reﬂect the new potential
beneﬁts (and risks) of today's tools.
One recent example is the NIH policy on the use of cloud comput-
ing to store and analyze controlled-access dbGaP data. When the
dbGaP policies were originally written, public cloud providers didn't
exist, and the internet itself was relatively new. As a result, the poli-
cies didn't provide clear guidance around the use of the cloud, leading
to a 2014 ban on cloud use until the policies could be clariﬁed. The
guidance was updated in March of 2015 — investigators may now re-
quest permission to use cloud computing services when submitting a
dbGaP Project Request, as long as they show that they are exercising
appropriate care in how they use those services (NIH, 2015). Policies
had lagged behind tools and become a bottleneck; they have now
caught up.
Another example is the evolution of consent. Today's technolo-
gy makes it easy for data collected by one organization to be se-
curely made available for analysis by many qualiﬁed researchers
in many locations. That ‘collect once, analyze often’ democratiza-
tion of access is a value multiplier for data. Unfortunately, many
of today's consent forms were written in a world of siloed
research, without anticipation of widespread sharing. New studies
(such as the MSSNG project, Autism Speaks, 2015) and newslating from pictures to text.
14 D. Glazer / Applied & Translational Genomics 6 (2015) 11–14work on the legal front (such as Sage's Portable Legal Consent
framework, Wilbanks, 2012) are helping policies catch up with
technology.
6. Going forward
The worlds of Atoms, Bits, and Cells are coming together to the
beneﬁt of all of us. We need ongoing collaboration from leaders in all
ﬁelds to collect more data, build better tools, and thoughtfully upgrade
our policies. Google Genomics is part of a growing movement to bring
progress from the last 20 years of data science to the world of life
science. Together, we can unlock the value in our information, and
make the vision of precision medicine real. It is within our reach to
fully transformmedicine— that very possibility gives us a responsibility
to achieve it.
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